(Q37772513)

22 August 2017

1 reference

title

Emerging drugs for Hodgkin's lymphoma (English)

1 reference

22 August 2017

Boris Böll

1

1 reference

22 August 2017

Peter Borchmann

series ordinal

2

1 reference

22 August 2017

Volker Diehl

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

15 July 2010

1 reference

Expert Opinion on Emerging Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

15

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

585-595

1 reference

Current strategies and new approaches in the treatment of Hodgkin's lymphoma

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Current approaches to the management of pediatric Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

New treatment strategies for Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Salvage therapy in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Are we improving the long-term burden of Hodgkin's lymphoma patients with modern treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Molecular pathogenesis of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Advances in biology, diagnostics, and treatment of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

The biology of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Late effects of Hodgkin's disease and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Hodgkin's lymphoma and CD30 signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Potent antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Circulating clonotypic B cells in classic Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Lymphoma stem cells: enough evidence to support their existence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

VEGF as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Anti-CD30 human IL-2 fusion proteins display strong and specific cytotoxicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Epstein-Barr virus and oncogenesis: from latent genes to tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Lenalidomide for the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Histone deacetylase inhibitors as anti-neoplastic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Histone deacetylase inhibitors: gathering pace

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

The pathogenesis of classical Hodgkin's lymphoma: what can we learn from analyses of genomic alterations in Hodgkin and Reed-Sternberg cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505602

10.1517/14728214.2010.505602

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference